42 results about "Vaccine adjuvant" patented technology

The present invention belongs to the field of microbiology, and particularly relates to membrane vesicles (MVs) isolated from bacteria, and an isolation and preparation system and method for the membrane vesicles, and applications of the membrane vesicles. The bacteria of the present invention comprise Gram-positive bacteria and Gram-negative bacteria. The invention uses ionizing irradiation to irradiate bacteria, and isolates and purifies the produced membrane vesicles. The membrane vesicles prepared can be used as a vaccine, a vaccine adjuvant and / or a pharmaceutical carrier. In addition, the present invention provides a biological composition comprising the membrane vesicles and inactivated bacteria. In addition, the present invention also provides a preparation system, and isolation and purification system for bacterial membrane vesicles and the corresponding method. The membrane vesicles obtained by using the system and method have high yield, high purity and easy to be industrialized.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

Lipidized oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. These compounds may have therapeutic applications in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders (SEE FORMULA).

The application discloses a kind of inactivated vaccine adjuvant storage equipment for cattle and sheep, it is related to the technical field of livestock vaccine storage, including box, the inner wall of box is fixedly connected with storage plate, eight storage components are arranged in the inner wall of storage plate, storage component includes body and base, body is rotatably connected with the inner wall of storage plate, base is fixedly connected with the inner wall of box, the inner wall of base is provided with the slot matched with body, top plate is arranged in body, further including jacking component and adaptive component, jacking component is arranged in base, so that when body rotates, top plate is vertically moved up, the position of top plate is controlled by the arrangement of adaptive component, at the same time, when body vertically moves down, the limit of top plate is removed, further including expansion component, expansion component is arranged on jacking component, the above-mentioned structure is cooperated with each other, and has the effect of convenient taking, improves the convenience of veterinarian operation.

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.

A method for preparing aluminum hydroxide dry powder and its sol, and its application, relates to the field of vaccine adjuvant preparation. The method includes: preparing an ammonia solution or sodium hydroxide solution; preparing an aluminum chloride solution; neutralizing the ammonia solution or sodium hydroxide solution with the aluminum chloride solution at 15-20°C to generate a milky white, translucent colloidal suspension; filtering; freeze-drying followed by aging to obtain aluminum hydroxide dry powder; adding the dry powder to a sodium chloride electrolyte solution, processing it in a high-speed shear disperser, redispersing the dry powder into a sol at a certain temperature, and homogenizing it cyclically in a high-pressure homogenizer to obtain aluminum hydroxide sol; removing electrolytes from the aluminum hydroxide sol using electrodialysis, followed by high-pressure sterilization and packaging. This invention solves the problems of clumping and sedimentation during sterilization and storage, poor stability, inconvenience in transportation and use, and limited concentration in existing aluminum hydroxide adjuvant preparation methods.

The present invention relates to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino- and carboxy-terminal regions of the amyloid-beta peptide (Aβ), the amino- and carboxy-terminal regions of the tau protein, and a T-cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's disease (AD). The chimeric antigen exerts its action by stimulating a multi-target humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This promotes the combined elimination of toxic Aβ and tau species from the brain, thereby preventing or significantly improving the clinical symptoms and neuropathology of AD.

This invention discloses a porcine CD40L trimer protein, a recombinant Bacillus subtilis strain expressing this protein, and its applications, belonging to the fields of microbial genetic engineering and livestock and poultry biological products technology. This invention utilizes Bacillus subtilis WB800N as a host and pHT43 as a vector to successfully construct a recombinant strain that efficiently secretes and expresses porcine CD40L trimer protein. Soluble expression of the porcine CD40L trimer protein was achieved. The amino acid sequence of the porcine CD40L trimer protein expressed by the recombinant strain is shown in SEQ ID NO:1. Immunological activity verification using this porcine CD40L trimer protein revealed that the CD40L trimer protein expressed in this invention can simultaneously activate humoral and cellular immunity, possessing practical application value as a novel vaccine adjuvant.

A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.

The application provides a kind of superparamagnetic micro-particle based on microbial template, the mass ratio of cobalt element and iron element in superparamagnetic micro-particle is (1-5):1;The content of iron element in superparamagnetic micro-particle is 18-75 mg / g, and the content of cobalt element is 18-375 mg / g.Simultaneously, the application also provides the preparation method and application of the superparamagnetic micro-particle.The superparamagnetic micro-particle can effectively load antigen protein, and then induce the body to produce long-term, efficient specific immune response, improve the protection ability, and can be applied to the preparation of vaccine adjuvant.

The application discloses a kind of composite water-soluble vaccine adjuvant and preparation method thereof, belong to biological medicine technical field.The adjuvant is based on the composite technology of water-soluble component and targeted delivery carrier, through the dual targeting effect of mannose modified beta-glucan, the uptake efficiency of dendritic cells to antigen is significantly improved, and the regulation of immune response is realized by synergistic levamisole.The adjuvant has the characteristics of uniform particle size, excellent water solubility, good storage stability, etc., and the immune enhancement effect is significantly better than traditional adjuvant, and can be widely used in the research and development of influenza, tuberculosis and tumor vaccines, has important clinical value and industrialization potential.

This invention relates to the field of vaccine adjuvant technology, and discloses an oil-in-water adjuvant containing squalene and α-tocopherol, its preparation method, and its application. The preparation method includes the following steps: mixing squalene, α-tocopherol, and poloxamer to obtain an oil phase mixture; subjecting the oil phase mixture to high-speed shearing with an aqueous phase to obtain a pre-emulsion; and subjecting the pre-emulsion to high-pressure homogenization to obtain the oil-in-water adjuvant. This invention, through the synergistic effect of α-tocopherol and poloxamer, combined with a specific preparation process, solves the problems of poor stability and uneven particle size distribution in existing adjuvants. The adjuvant prepared by this invention exhibits excellent long-term physicochemical stability, with a Z-average particle size in the range of 100-300 nm and a polydispersity index (PDI) of less than 0.25, demonstrating good immunostimulant carrying capacity and immune enhancement effect.

This disclosure relates to antigen-encoding RNAs and other polynucleotides that can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidine or a fragment thereof. This disclosure also relates to the use of RNA, polynucleotides, or compositions in methods for inducing an immune response in a subject.

The application discloses a use of ursolic acid as a SARS-CoV-2 subunit vaccine adjuvant, aims to solve the technical problems of relatively weak immunogenicity of existing subunit vaccines, possible local or systemic adverse reactions of some adjuvants and unclear action mechanism, and provides a new medical use of ursolic acid. The ursolic acid can effectively improve the antigen-specific antibody level of the subunit vaccine immunized mice, promote the formation of germinal centers and enhance follicular helper T cell response. The action mechanism is that after the ursolic acid is combined with PTPRF, the stability of the PTPRF is affected and the degradation of the PTPRF is promoted, thereby enhancing the downstream STAT3 phosphorylation, promoting the expression of antigen presentation related genes and improving the antigen presentation ability of the dendritic cells, and finally enhancing the antibody response of the body. The application provides a new subunit vaccine adjuvant candidate molecule for preventing severe SARS-CoV-2 related infections in clinic, and provides a new molecular target and mechanism basis for the development of subunit vaccine adjuvants.

The application discloses a polypeptide for presenting a heterologous protein to an outer membrane vesicle and application thereof. Specifically disclosed are a polypeptide with an amino acid sequence of SEQ ID No. 1 and application thereof in presenting a heterologous protein to an outer membrane vesicle of a host bacterium. The application successfully expresses the heterologous protein in OMVs of Xanthomonas campestris by connecting the polypeptide with the heterologous protein. Xanthomonas campestris is a plant pathogenic bacterium, has low immunogenicity to human bodies, has a unique advantage for biomedical application of OMVs, and realizes presentation of the heterologous protein in Xanthomonas campestris OMVs for the first time, thereby providing a solution for future plant biotechnology, development and application of a vaccine adjuvant and the like. The polypeptide of the application realizes presentation of the heterologous protein by using only 25 amino acids, and can minimally affect the conformation and activity of the presented protein.

This invention provides a composite adjuvant, its preparation method, and its application in vaccine preparation, belonging to the field of vaccine adjuvant technology. The composite adjuvant of this invention has low viscosity, only 12 mPa·s at 20°C, ensuring smooth injection; it exhibits high biocompatibility, with no deaths or organ abnormalities in acute toxicity experiments in mice, and no local or systemic adverse reactions or stress responses in chickens after injection; it also demonstrates excellent immunogenicity, achieving a 90% seroconversion rate for Mycoplasma cambogia and an 80% seroconversion rate for Mycoplasma synoviae 28 days after immunization with an inactivated Mycoplasma synoviae vaccine.

The present invention provides CR2 binding proteins which bind to human CR2, pharmaceutical compositions comprising said CR2 binding proteins and their use in the treatment or prevention of autoimmune and / or inflammatory conditions, infectious diseases and malignancies associated with the Epstein-Barr virus (EBV); and their use as vaccine adjuvants / antigen carriers.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

This invention relates to a composite adjuvant, its preparation method, and its application. The composite adjuvant comprises a first component and a second component. The first component is an aluminum adjuvant that adsorbs a cyclic dinucleotide, and the second component is an aluminum adjuvant that adsorbs monophospholipid A. The mass ratio of the cyclic dinucleotide to the aluminum adjuvant in the first component is 1:(2-20), and the mass ratio of monophospholipid A to the aluminum adjuvant in the second component is also 1:(2-20). When used in combination with various antigens, the composite adjuvant of this invention can effectively enhance the immune response induced by vaccines, with a significantly better enhancement effect than that of a single adjuvant. The composite adjuvant of this invention is low in cost and has good safety, and can be used as a candidate adjuvant for various vaccines, providing new ideas for the development and application of novel vaccine adjuvants.

The present application relates to a kind of nucleotide, vaccine comprising it and composite vaccine adjuvant.The sequence of the nucleotide is shown as SEQ ID No:1.Relative to conventional technology, the beneficial effects of the present application include: the present application adopts new optimized sequence, provides a kind of nucleotide, the nucleotide can be as CpG oligonucleotide adjuvant, induces vaccine antigen to produce stronger humoral immunity, cellular immunity level and anti-tumor immune effect etc., has obvious clinical application value and vaccine development value.Moreover, using the immunoadjuvant of the present application helps to reduce the dose of clinical use vaccine, improves safety.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

This invention discloses a sodium caseinate-based Pickering emulsion, its preparation method, and its application, belonging to the field of vaccine adjuvant technology. This invention is the first to propose using Salmonella Typhimurium flagellin and sodium caseinate as raw materials to formulate a Pickering emulsion. The prepared Pickering emulsion has the characteristics of small particle size, good biocompatibility, and high stability, and can induce a high immune response in the body. This invention is also the first to propose the application of the Pickering emulsion formulated using Salmonella Typhimurium flagellin and sodium caseinate as raw materials as a vaccine adjuvant. The Pickering emulsion prepared by this invention has a simple preparation process, requiring only mixing and homogenization, and can effectively load the model antigen OVA. This emulsion has good cellular safety and can promote the endocytosis of exogenous antigens by macrophages. The emulsion can induce the body to produce high levels of antibody titers, with antibody titers reaching more than 120,000 times.

The application discloses a kind of synthesis method of spherical polymer nanoparticles, it is related to vaccine technical field, and the method comprises the following steps: polyvinylpyrrolidone is dissolved in mixed solvent, then glyoxal, ascorbic acid and ethylenediamine are added in turn respectively, after stirring for a certain time, the color of solution obviously changes from yellowish to wine red.The solution containing prepolymer is transferred into reaction kettle, the reaction kettle is put into oven to react, the previous prepolymer will further crosslink and polymerize, form nonlinear network polymer skeleton, through repeated centrifugation and ethanol washing, finally drying can obtain the target spherical nanoparticle material.The application uses ascorbic acid as raw material, ethylenediamine as initiator and connecting agent, glyoxal as crosslinking agent, successfully synthesizes a kind of brand-new polymer nanoparticle, simultaneously realizes efficient antigen delivery and specific activation B cell, and is a kind of brand-new ideal vaccine adjuvant with promising application.

This invention discloses a stabilized emulsion, its preparation method, and its uses. The invention stabilizes the emulsion using aluminum hydroxide microgels. The stabilized emulsion comprises an oil phase, an aqueous phase, and a composite stabilizer adsorbed at the oil-water interface or dispersed in the aqueous phase. Adding charged particles that interact with the aluminum hydroxide microgels to the stabilizer further enhances the emulsion's stability and immune response. The stabilized emulsion of this invention can be used as an oil-emulsion adjuvant, exhibiting uniform particle size, good dispersibility, good stability, and tunable properties. It can simultaneously activate humoral and cellular immune responses and can be used as a vaccine adjuvant or in vaccine delivery systems for preventative and therapeutic vaccines.

The application relates to the technical field of medicines, and particularly discloses a novel immune stimulant, a preparation method and application thereof. The immune stimulant comprises an alpha-mannose modified imidazoquinoline derivative, an N-acetyl cysteine modified cytosine-guanine dinucleotide, a glycyrrhetinic acid-polyethylene glycol derivative, a phytic acid-glycine oligomer, a medicinal excipient and water for injection, three modified active ingredients are bridged by the phytic acid-glycine oligomer as a bridging unit, and a ternary coordination complex is formed through dynamic non-covalent coordination. The preparation method comprises the following steps: after raw materials are pretreated, the active ingredients are premixed, dissolved and solvent is recovered, then dynamic coordination reaction, ultrafiltration purification and concentration are carried out, and finally, a finished product is obtained through double-cavity preparation forming. The immune stimulant can be used for preparing a tumor immunotherapy, an anti-infection treatment, an immune deficiency disease auxiliary treatment drug or a vaccine adjuvant, and has the advantages of high active ingredient stability, good in-vivo delivery efficiency and outstanding synergistic effect.

A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.

This invention discloses an assessment method and system for predicting the immunogenicity of vaccine adjuvants using machine learning, relating to the field of vaccine adjuvant R&D technology. The method includes dividing antigen homology clusters and adjuvant backbone clusters based on candidate sample units, and adding cluster labels to the candidate sample units to obtain standard sample units. This invention jointly models adjuvant structural features with antigen protein sequence features and introduces the consistency of immune response stages into the historical experimental sample screening process. This expands the selection criteria for historical reference samples from static similarity to matching immune evolution stages. Based on local adaptive measurement and local linear reconstruction, the main predicted immunogenicity value is structurally corrected, enabling the influence of historical samples on current candidate samples to adaptively change with the degree of local structural adaptation. This makes the immunogenicity classification and adjuvant selection more targeted and stable.